Parkinson's Disease Drug Market Regional Analysis

Global Parkinson'S Disease Drug Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 11.39 billion in 2024 to USD 11.39 billion by 2032, growing at a CAGR of 10.6% during the forecast period (2025-2032). 

The market for medications for Parkinson's disease is getting increasingly competitive. The market is becoming more active as a result of recent product launches and the large number of medicines in the product pipelines of multinational pharmaceutical companies. A number of new products are expected to be released, which could significantly alter the market shares of pharmaceutical companies that are currently engaged in the market, over the forecast period. 'AbbVie Inc. (USA) ', 'Novartis AG (Switzerland) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'UCB S.A. (Belgium) ', 'GlaxoSmithKline plc (UK) ', 'Merck & Co., Inc. (USA) ', 'Boehringer Ingelheim (Germany) ', 'Lundbeck A/S (Denmark) ', 'Acadia Pharmaceuticals Inc. (USA) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Amneal Pharmaceuticals, Inc. (USA) ', 'Supernus Pharmaceuticals, Inc. (USA) ', 'Kyowa Kirin Co., Ltd. (Japan) ', 'Orion Corporation (Finland) ', 'Neurocrine Biosciences, Inc. (USA) ', 'Acorda Therapeutics, Inc. (USA) ', 'Ipsen S.A. (France) ', 'Luye Pharma Group (China) ', 'NeuroDerm Ltd. (Israel) (acquired by Mitsubishi Tanabe Pharma) ', 'Revance Therapeutics, Inc. (USA) '

The increasing aging population and the rising number of Parkinson's cases: Rising aging populations and increased prevalence of neurological illnesses are two important factors driving the growth of this market. With the increase in the number of patients with Parkinson’s disease, the demand for the drugs required for the treatment of this disease, is also increasing rapidly. This is expected to support the growth of the parkinson’s disease drug market globally, over the forecast period.

Increasing research and development for treatment of Parkinson’s disease: A key trend in the market for Parkinson's treatments is the rise in government and corporate funding for research and development of Parkinson's disease medications. Companies involved in the drug development for this disease are working towards developing new and innovative drugs for the treatment of the disease. Therefore, the market for Parkinson’s disease drugs is expected to be supported by rising investments in the development of Parkinson's drugs.

Based on the region, the European region currently dominates the Parkinson's disease drug market with respect to market share. Due to the rising prevalence of Parkinson's disease and active government assistance through government-assisted pharmacies, Europe commands the worldwide Parkinson's disease market. However, North America is predicted to hold the largest market share for Parkinson's disease medications due to increased research & development spending and the anticipated approval and launch of new pipeline drug candidates, over the forecast period.